Marta Figueiredo, PhD, science writer —

Note: This story was updated June 28, 2023, to correct the time frame of the ADAPT-SC+ clinical trial, in which patients will be treated for up to 3.5 years. The U.S. Food and Drug Administration (FDA) has approved Argenx’s under-the-skin formulation of efgartigimod, now called Vyvgart Hytrulo,…

Generalized myasthenia gravis (gMG) may be associated with a deficiency in a type of immune cell called myeloid-derived suppressor cells (MDSCs), a study suggests, and that restoring their function and increasing their numbers may help reduce symptoms. Treatment with immunosuppressants resulted in an expansion of MDSCs, which was linked…

Descartes-08, Cartesian Therapeutics’ investigational CAR T-cell therapy, appears generally safe and markedly lessened symptom severity in the first five patients with generalized myasthenia gravis (gMG) enrolled in a Phase 1b/2a clinical trial. “I am very encouraged by the interim analysis findings,” as the therapy “appears safe and well…

Both zilucoplan and rozanolixizumab, UCB’s experimental therapies for generalized myasthenia gravis (gMG), safely and effectively reduced symptom severity and their impact on daily activities, while improving patients’ quality of life, top-line data from two Phase 3 trials show. Zilucoplan works by blocking the complement system, a part…

Myasthenia gravis (MG) patients with antibodies against the thyroid gland have significantly more B-cells — the immune cells that produce antibodies — and fewer immune T-cells, a small single-center study in China shows. These early findings suggest the presence of anti-thyroid antibodies may affect the success of immunomodulating therapies…

Fufang Huangqi decoction — a traditional Chinese medicine formula reported to reduce symptoms of myasthenia gravis (MG) — helps to restore the balance of gut microbial community, or microbiota, in people with mild MG, according to a small study. These early findings suggest that the formula’s clinical benefits may…

The dynamics of mitochondria — the cells’ powerhouses — and their associated energy metabolism are highly affected in people with myasthenia gravis (MG), a study shows. Notably, the levels of several proteins involved in mitochondrial dynamics and health were found to be significantly reduced in MG patients, and many of…

Men with late-onset myasthenia gravis (MG) show poorer memory and spatial orientation, as well as lower-than-normal volumes of brain regions involved in such functions, than their healthy peers, according to a small single-center study in Germany. These findings add to a number of studies reporting cognitive deficits in MG…

To celebrate Rare Disease Day, on Feb. 28, Janssen has launched a refreshed national campaign, called iMaGineMyMG, to increase awareness about myasthenia gravis (MG), provide support to people living with the disease and their families, and open up opportunities for potential research. The company has redesigned the campaign’s…

Zilucoplan, UCB’s experimental therapy, safely and effectively eases symptom severity and improves the quality of life for adults with generalized myasthenia gravis (gMG), while helping them complete daily activities, according to top-line data from the Phase 3 RAISE clinical trial. Based on these findings, indicating the trial met its…